Freenome Holdings, Inc.
Freenome is a biotechnology company dedicated to early cancer detection through a comprehensive multiomics platform that uses a standard blood draw. Combining molecular biology, computational biology, and machine learning, Freenome develops noninvasive blood tests to detect cancer at its earliest, most treatable stages, aiming to make cancer screening accessible and effective for everyone.
Industries
Nr. of Employees
large (251-1000)
Freenome Holdings, Inc.
South San Francisco, California, United States, North America
Products
Blood-based colorectal cancer screening test (multiomics, regulatory submission in progress)
A multiomics blood test combining genomic, epigenomic, and proteomic signals with machine learning to detect colorectal cancer and high-risk lesions from a standard blood draw; performance validated in a large prospective registrational study and published in a peer-reviewed journal.
Autoantibody-based lung cancer blood test (CE‑IVD marked, acquired capability)
A CE‑IVD–marked blood-based autoantibody assay used for lung cancer detection and to aid risk stratification in targeted screening programs; acquisition provides access to an established autoantibody discovery platform and commercial assay experience.
Blood-based colorectal cancer screening test (multiomics, regulatory submission in progress)
A multiomics blood test combining genomic, epigenomic, and proteomic signals with machine learning to detect colorectal cancer and high-risk lesions from a standard blood draw; performance validated in a large prospective registrational study and published in a peer-reviewed journal.
Autoantibody-based lung cancer blood test (CE‑IVD marked, acquired capability)
A CE‑IVD–marked blood-based autoantibody assay used for lung cancer detection and to aid risk stratification in targeted screening programs; acquisition provides access to an established autoantibody discovery platform and commercial assay experience.
Services
Biomarker development collaborations
Collaborative programs to identify and validate molecular and protein biomarkers for diagnostic and drug-response applications with pharmaceutical and academic partners.
Clinical study design and operational support
Design and operationalization of large-scale prospective clinical trials with hybrid recruitment and site networks to validate blood-based screening tests.
Population health and EMR integration services
Solutions that combine multiomic testing with real-world clinical data and electronic medical record integration to support population-health workflows and care-pathway optimization.
Machine learning model development and deployment
Development and deployment of AI models for diagnostic classification using multiomic datasets and feedback loops from clinical data.
Biomarker development collaborations
Collaborative programs to identify and validate molecular and protein biomarkers for diagnostic and drug-response applications with pharmaceutical and academic partners.
Clinical study design and operational support
Design and operationalization of large-scale prospective clinical trials with hybrid recruitment and site networks to validate blood-based screening tests.
Population health and EMR integration services
Solutions that combine multiomic testing with real-world clinical data and electronic medical record integration to support population-health workflows and care-pathway optimization.
Machine learning model development and deployment
Development and deployment of AI models for diagnostic classification using multiomic datasets and feedback loops from clinical data.
Expertise Areas
- Early cancer detection using blood-based assays
- Multiomics profiling and integration
- Machine learning for diagnostics and biomarker discovery
- Clinical trial design and registrational study execution
Key Technologies
- Cell-free DNA sequencing
- Methylation profiling
- Proteomics / quantitative protein assays
- Autoantibody profiling